Theranostics in Japan

Frankly, Japan is at the end of the line of current clinical theranostics such as PRRT and PSMA. Many patients go abroad for PRRT and PSMA treatment. This lamentable situation has been caused mainly by the strict regulations as well as the limited number of isolation rooms available for these purposes in this country. But despite this, Japanese scientists are developing several unique activities in theranostics, including 211At[NaAt] for 131I radioiodine refractory thyroid cancer and meta-211Atastato- benzyl guanidine (211At-MABG) for 131I-MIBG refractory pheochromocytoma/ paraganglioma, which are currently ready for investigator-initiated trial. There are several other developments in this field. Such information is described in this short article.